Business
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that data from its PRAX-944 essential tremor (ET) program will be presented at the upcoming 2022 American Academy of Neurology (AAN) Annual Meeting, which will take place in Seattle, Washington from April 2 – 7, 2022 and virtually from April 24 – 26, 2022. Abstracts can be accessed on the AAN meeting website. “Essential tremor is the most common movement disorder, yet ET patients have limited treatment options that inadequately control tremor and do so with poor tolerability, leading to high discontinuation rates,” said Bernard Ravina, M.D., chief medical officer of Praxis. “We are focused on fundamentally changing the way that ET patients are treated by developing two novel and differentiated treatments with potential to have a positive impact on patients’ lives.” Oral Presentation Details: Translational Pharmacology of PRAX-944, a Novel T-type Calcium Channel Blocker for the Treatment of Essential Tremor Format: Oral PresentationSession Date/Time: April 6 at 5:06 p.m. PTSession Name: Movement Disorders: Dystonia and Tremor DisordersProgram Number: S32.009 T-type calcium channels (TTCCs) play a critical role in regulating neuronal activity within the cerebello-thalamo-cortical (CTC) circuitry, which is responsible for coordinated movement, and when dysregulated, can generate tremor. In rats, PRAX-944 reduced sigma-power, a translational biomarker to measure drug effect on TTCCs, at concentrations that reduced tremor without locomotor side-effects. In healthy participants, comparable sigma-power reductions indicate that TTCC blockade was achieved at well-tolerated doses that may hold therapeutic promise for tremor reduction in patients with ET. These findings have recently been published in Movement Disorders DOI: 10.1002/mds.28969. Virtual Presentation Details: These presentations will be available April 24 – 25, 2022 during AAN’s Virtual Experience. PRAX-944-221: A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor Findings from the o...